publication date: Apr. 18, 2016

Caligiuri Named AACR President-Elect 

 

Michael Caligiuri was named president-elect by the members of the American Association for Cancer Research. He will officially become president-elect at the AACR’s annual meeting in New Orleans, April 16-20, and will assume the presidency at the 2017 annual meeting.

Caligiuri is director of The Ohio State University Comprehensive Cancer Center and CEO of the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. He holds the John L. Marakas Nationwide Insurance Enterprise Foundation chair in cancer research and is a professor in The Ohio State University College of Medicine Departments of Molecular Virology, Immunology and Medical Genetics and Internal Medicine.

Caligiuri is known for his work in immunology, which is focused on human natural killer cells and their modulation for the treatment of leukemia, myeloma, and glioblastoma.

“This is an especially exciting time as we all work to forge new and innovative models of collaboration between academia, industry, the government and the community—something I am certain AACR can play a pivotal role in facilitating,” said Caligiuri.

Caligiuri has been involved with AACR since 1990, and was elected by the membership to the AACR board of directors in 2013. He has served as chairperson of the Publications Committee and as a member of the Clinical and Translational Cancer Research Committee. He has also served as a member of the Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research Committee; Landon Foundation-AACR INNOVATOR Award for Cancer Prevention Research Scientific Review Committee; Pezcoller Foundation-AACR International … Continue reading 42-14 Caligiuri Named AACR President-Elect

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.